Olive Leaf Extract Lowers Blood Pressure Comparably to Drug
Benolea EFLA 943 olive leaf extract was shown to be as effective as the hypertension drug Captopril in lowering blood pressure.
Frutarom’s (Wadenswil, Switzerland) Benolea EFLA 943 olive leaf extract was shown to be as effective as the hypertension drug Captopril in lowering blood pressure, according to recent study results the company presented at the Vitafoods trade show in May.
Conducted at the University of Indonesia, the randomized, double-blind, double-dummy, active controlled study involved 232 participants ages 25 to 60 years with stage-1 hypertension. During the treatment period, subjects were either given one 500-mg Benolea supplement or one 12.5-mg Captopril tablet, both taken twice a day.
According to Frutarom, the researchers found that both Benolea and Captopril effectively lowered systolic and diastolic blood pressure in a comparable manner, compared to baseline.
Moreover, Benolea was found to significantly reduce total cholesterol and plasma triglyceride levels, while the conventional drug did not. “Particularly in participants with high baseline triglyceride levels (>200 mg/dl), the reduction was remarkable: the triglycerides diminished by 53.13 mg/dl. Such positive effects were not observed in the Captopril group,” Frutarom stated.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.
